Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Diet-induced weight loss tied to altered brain connectivity
Individuals with obesity who underwent a short-term, low-calorie diet demonstrate a multifaceted body response, including an increased brain connectivity in the limbic‒temporal network (emotion and memory) as well as hormone and eating behaviour changes that seem relevant for recovering the weight lost, a recent study has shown.
Diet-induced weight loss tied to altered brain connectivity
30 Jul 2024
Does race/ethnicity affect the safety, efficacy of semaglutide?
A post hoc analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trials has shown that the treatment effect and safety profile of semaglutide 2.4 mg, compared with placebo, are consistent across racial and ethnic subgroups.
Does race/ethnicity affect the safety, efficacy of semaglutide?
29 Jul 2024
Study presents alternate treatment approach for EARLY T2D
In the EARLY* trial, a 16-week intervention consisting of a 5:2 intermittent fasting meal replacement (5:2 MR) diet trumps two antidiabetic agents in improving glycaemic control and weight loss, as well as BP, TG, and HDL-C** levels in overweight or obese Chinese individuals with newly diagnosed type 2 diabetes (T2D).
Study presents alternate treatment approach for EARLY T2D
29 Jul 2024
Real-world data favour tirzepatide over semaglutide for weight loss
Tirzepatide appears to yield substantially greater reductions in weight than semaglutide in the real-world treatment of overweight or obesity in adults with or without diabetes, according to a study.
Real-world data favour tirzepatide over semaglutide for weight loss
25 Jul 2024
Pioglitazone giúp giảm thêm HbA1c và ngăn tăng ceton máu
Một nghiên cứu được trình bày tại ADA 2024 cho thấy việc bổ sung pioglitazone ở bệnh nhân đái tháo đường (ĐTĐ) típ 1 đang điều trị bằng thuốc ức chế SGLT2, như dapagliflozin, giúp tăng cường hiệu quả giảm HbA1c và ngăn tình trạng tăng ceton máu do thuốc ức chế SGLT2. Kết quả này tạo tiền đề để các nghiên cứu dài hạn về kết cục trên tim mạch và thận ở bệnh nhân ĐTĐ típ 1 được tiến hành một cách an toàn.